Key result
A 47-year-old female with primary ovarian angiosarcoma treated with surgery, radiotherapy, Olaparib, and anti-PD-1 immunotherapy survived without evidence of disease recurrence at 9 months.
Why the study?
Diagnosis of primary ovarian angiosarcoma remains challenging due to non-specific clinical symptoms and morphological confusion with other malignant neoplasms.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Primary ovarian angiosarcoma is a rare malignancy where targeted therapy (PARP inhibitors) and immunotherapy (anti-PD-1) may serve as potential treatment options following surgical resection.
The diagnosis of primary angiosarcoma of ovary is still a challenge as it has no specific clinical symptoms and is easily confused with other malignant neoplasms in morphology. Here, we described a case of primary ovarian angiosarcoma and reviewed the literature. A 47-year-old female showed a left ovary mass. Grossly, the cut surface of the tumor was solid and gray-white with intermediate texture. Some areas were spongy and atropurpureus with a soft texture. Microscopically, the tumor cells were arranged into a variety of different structures with visible hemorrhage. Immunochemically, the tumor cells were positive for CD31, ERG, Fli1, D2-40 and vimentin in a strong and diffused manner. CD34 stain showed focal positivity. Epithelial markers (e.g. CK, CK7, CK8/18 and PAX8) were all negative. Negative immunostaining for SMA, S-100, P53 and calretinin also were detected. The proliferative index (Ki-67) was approximately 40%. After surgery, the patient was treated with radiotherapy, targeted therapy and immunotherapy. In the 9-month follow-up, the patient was survival without evidence of disease. The diagnosis of ovarian angiosarcoma required the careful observation of morphology and the reasonable application of immunohistochemistry. Targeted therapy and immunotherapy are the potential directions for the treatment of angiosarcoma.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2021) conducted a case report in Primary ovarian angiosarcoma (n=1). Surgery, radiotherapy, Olaparib, and anti-PD-1 immunotherapy was evaluated on Disease-free survival. A 47-year-old female with primary ovarian angiosarcoma treated with surgery, radiotherapy, Olaparib, and anti-PD-1 immunotherapy survived without evidence of disease recurrence at 9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: